FDA Calls NEO212 CMC Approach Reasonable, Advises Bioavailability Study for Tablet Switch
NTHI is trading near its 52-week low of $3.6 (9.7% above the low) on elevated volume (1.8× avg).
Summary
The FDA provided written feedback on NEO212's CMC development, calling the proposed approach reasonable — a key de-risking step for the brain tumor therapy. The agency also recommended an in vivo bioavailability study to support switching from capsule to tablet, and outlined specific CMC tasks before confirmatory trials. This follows a series of regulatory wins, including IND approvals in Abu Dhabi for NEO212 and NEO100, and comes amid significant financing activity and governance concerns. The feedback clears a path toward late-stage development, though the company still faces a going concern warning and heavy dilution risk from recent capital raises.
At the time of this announcement, NTHI was trading at $3.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $95.4M. The 52-week trading range was $3.60 to $12.99. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.